Allianz SE Invests $346,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Allianz SE purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,886 shares of the medical equipment provider's stock, valued at approximately $346,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Pictet Asset Management Holding SA raised its holdings in Lantheus by 12.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after buying an additional 1,113 shares during the period. New Age Alpha Advisors LLC acquired a new stake in Lantheus in the 4th quarter valued at approximately $1,365,000. Norges Bank purchased a new stake in Lantheus in the fourth quarter valued at approximately $26,189,000. Homestead Advisers Corp lifted its stake in Lantheus by 39.5% during the fourth quarter. Homestead Advisers Corp now owns 50,500 shares of the medical equipment provider's stock worth $4,518,000 after purchasing an additional 14,300 shares in the last quarter. Finally, NEOS Investment Management LLC boosted its position in shares of Lantheus by 10.8% during the fourth quarter. NEOS Investment Management LLC now owns 7,962 shares of the medical equipment provider's stock worth $712,000 after buying an additional 779 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several research reports. B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. JMP Securities restated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. Finally, Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Insider Buying and Selling

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 over the last 90 days. 2.00% of the stock is owned by insiders.

Lantheus Stock Down 6.5 %

Lantheus stock traded down $6.29 during trading on Friday, reaching $90.92. The stock had a trading volume of 1,158,346 shares, compared to its average volume of 944,377. Lantheus Holdings, Inc. has a 52-week low of $58.46 and a 52-week high of $126.89. The business has a 50 day moving average price of $93.31 and a 200 day moving average price of $96.18. The stock has a market cap of $6.23 billion, a PE ratio of 15.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.